Clinical Genomics has a long and successful history in the field of colorectal cancer (CRC) screening and diagnosis:

2016
  • Establishment of US-based molecular diagnostic pathology lab in Bridgewater, N.J.
2015
  • Four peer-reviewed journal articles published documenting clinical validity of Colvera™ in over 3,400 patients
2013
  • Acquires Enterix from Quest Diagnostics as part of expanded collaboration with Clinical Genomics
2010
  • Clinical Genomics demonstrates initial proof of concept of a blood test for CRC
2006
  • Clinical Genomics founded by members of the Enterix team, with ongoing support from Quest Diagnostics, after Enterix was sold to Quest Diagnostics, to develop genetic technology to detect CRC
2004
  • Enterix obtains nationwide coverage and payment policies from private health insurance companies for the use of FIT tests for CRC screening
2003
  • Enterix obtains a positive National Coverage Determination from CMS for the use of FIT tests for CRC screening
  • Quest Diagnostics selects InSure as its nationwide FIT test
2002
  • Enterix works with Congress and CMS to change federal law to allow Medicare to provide coverage and pay for innovative new CRC screening tests such as InSure
2001
  • InSure obtains US FDA 510(k) approval
2000
  • InSure introduced in the Australian market
1997
  • Enterix begins development of the innovative InSure brush-based Fecal Immunochemical Test (FIT)